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ABSTRACT: Oridonin (1) is a complex ent-kaurane
diterpenoid exhibiting remarkable antitumor activity. However,
the detailed mechanism or cellular target that underlies this
activity has not yet been identiﬁed. Herein, we report an
eﬃcient approach for exploring the anticancer mechanism of
oridonin through development of the potent ﬂuorescent
analogues. A series of novel ﬂuorescent oridonin probes linked
with coumarin moieties were designed, synthesized, and
characterized. Fluorescence microscopy and confocal imaging
studies suggested that ﬂuorescent oridonin probe 17d was
rapidly taken up into tumor cells and the mitochondrion was
the main site of its accumulation. Moreover, we conﬁrmed that
cytochrome c played an important role in oridonin induced mitochondrion-mediated apoptosis and α,β-unsaturated ketone is the
active moiety of oridonin, which is crucial to its uptake, localization, and cytotoxicity. Our results provide new insights on the
molecular mechanism of oridonin and would be useful for its further development into an antitumor agent.
■ INTRODUCTION
In the last few decades, natural products have remained an
important source for anticancer drug discovery.1,2 Isodon
species are widely distributed plants, and more than 600
diterpenoids have been isolated from this species over the past
30 years.3 Many Isodon diterpenoids have been tested in
laboratory assays against tumor cells, and a few compounds
have shown potent antiproliferative activity with low toxicity,
especially those with an ent-kaurane skeleton such as oridonin
(1),4 eriocalyxin B (2),5 longikaurin A (3),6 nodosin (4),7 and
so on (Figure 1, 1−5).8 The unique skeletons as well as their
potent antitumor activities have made these diterpenoids
promising candidates as anticancer agents.9
Oridonin (1) has been attracting increasing attention in
recent years by cancer biologists due to its remarkable
antitumor activity.10−13 Evidence has suggested that oridonin
exerts extensive antineoplastic activities against various human
cancer cells while exhibiting relatively low toxicity.14 This
unique and safe anticancer pharmacological proﬁle of oridonin
stimulated interest in the research of its mechanism of
anticancer action and structural modiﬁcations. Previous studies
have revealed that oridonin could induce cell cycle arrest,
apoptosis, and autophagy15 by regulating a series of transcrip-
tional factors.16,17 For instance, Bu et al. reported that oridonin
could induce apoptosis via p53- and caspase-dependent
induction of p38 MAPK in SW1990 pancreatic cancer cells.18
Xu et al. revealed that in pancreatic cancer BxPC-3 cells,
oridonin could up-regulate p53 and down-regulate CDK1,
which led to cell cycle arrest in the G2/M phase.19 Additionally,
Tommasi employed a mass spectrometry-based chemical
proteomics approach to uncover target proteins of oridonin
and suggested HSP70 1A as a potential target for oridonin in
Jurkat cells.20
In spite of the preclinical success of oridonin, its detailed
anticancer mechanism, mode of action, and intracellular target
remain elusive. Further development of oridonin for cancer
therapy was hampered largely due to these weaknesses.
Therefore, expanding the scarce knowledge of the antineo-
plastic molecular mechanism and potential binding proteins of
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oridonin for further rational new drug design is an unmet need.
More importantly, a systematic approach to target elucidation
would facilitate both the introduction of new drugs into clinical
practice and undesired targets identiﬁed.21 However, discover-
ing these functional targets and clarifying the mechanisms of
bioactive natural products have proven to be especially
perplexing due to the structural complexity of natural products,
low abundance of targets in vivo, and limitations of
bioanalytical methods.22
Despite these obstacles, a number of remarkable strategies
have been developed to tackle these challenges.23,24 Fluo-
rescence imaging is such a strategy that has been widely used to
visualize cell events and associated phenotypes at many levels,
from molecules to complete organisms.25,26 In recent years,
natural products linked to ﬂuorescent organic dyes for
Figure 1. Structures of typical natural ent-kaurane diterpenoids.
Figure 2. Structures of reported ﬂuorescent natural product probes.
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ﬂuorescence imaging has become a powerful tool to explore
biological phenomena and provide insights into their
mechanisms of action at many levels.27,28 Reports for the use
of bioactive ﬂuorescent probes from natural products to
investigate their modes of action and unveil the cellular
processes including cellular uptake, localization, or speciﬁc
Scheme 1. Synthesis of Fluorescent Oridonin Probes 17a−ea
aReagents and conditions: (a) ethylpropanedioate, piperidine, MeOH, reﬂux, overnight; (b) 10% NaOH, rt, 24 h; (c) corresponding diols, DMAP,
EDCI, CH2Cl2, rt, 8−48 h; (d) glutaric anhydride or succinic anhydride, DMAP, CH2Cl2, rt, 48−72 h; (e) EDCI, DMAP, CH2Cl2, rt, 0.5−2 h.
Scheme 2. Synthesis of Fluorescent Oridonin Probes 24a−ca
aReagents and conditions: (a) MeOH, ZnCl2, reﬂux, overnight; (b) 10% NaOH, rt, 24 h; (c) corresponding diols, DMAP, CH2Cl2, rt, 12−18 h; (d)
glutaric anhydride or succinic anhydride, DMAP, CH2Cl2, rt, 48−72 h; (e) EDCI, DMAP, CH2Cl2, rt, 0.5−1 h.
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interactions have already been developed (Figure 2, 6−
11).29−34 In these cases, the application of ﬂuorescent natural
product probes has greatly contributed to the investigations of
their modes of action and provided tools for visualization of
their targets.
This perspective led us to develop ﬂuorescent oridonin
analogues that retain their cytotoxicity and yet has properties
that facilitate its visualization within cells. We predicted that
these novel ﬂuorescent oridonin probes could provide insight
into understand the subcellular localization, anticancer
mechanism ,and structure−activity relationships (SARs) of
oridonin and ultimately accelerate the development of oridonin
as cancer therapeutics. Herein, we describe the design and
synthesis of a series of novel ﬂuorescent oridonin analogues and
the application of these probes in revealing the anticancer
action of oridonin.
■ RESULTS AND DISCUSSION
Design and Synthesis of Fluorescent Oridonin
Probes. Fluorescent probes of natural products are typically
generated by the attachment of a ﬂuorophore to natural
product via a proper linker, leaving the binding interactions
unaltered. However, these interactions are often aﬀect by linker
type, length, and attachment point. Fortunately, our previous
SARs analysis has revealed that the modiﬁcation on 14-hydroxyl
group of oridonin did not diminish its antiproliferative activity
against a panel of human cancer cell lines.35 With this in mind,
ﬂuorescent oridonin probes were designed and synthesized by
connecting 14-hydroxyl group of oridonin with diﬀerent
coumarin moieties through linkers of various lengths.
Speciﬁcally, highly ﬂuorescent N,N-dialkyl-7-aminocoumarin
derivatives (14, 21, Schemes 1 and 2) were employed as
ﬂuorescent moieties because these ﬂuorescent dyes has no
toxicity and oﬀer synthetic ﬂexibility.36,37
As depicted in Scheme 1, ﬂuorescent oridonin probes (17a−
e) were synthesized from commercially available oridonin (1)
in ﬁve steps. 7-(Diethylamino)coumarin-3-carboxylic acid (14)
was ﬁrst synthesized by the reaction of substituted
salicylaldehyde (12) with ethylpropanedioate by using
piperidine as the catalyst in methanol, followed by the
hydrolysis of the corresponding coumarin ester (13) with
10% NaOH aqueous solution at room temperature in 56%
overall yield over two steps. Because the length of the linkers
may inﬂuence the hydrophobicity of the labeled molecules,
diverse diols and anhydride handles were employed to further
extend the variability of linker’s length. For example, compound
15c was obtained by the treatment of 14 with 1,4-butanediol
(10 equiv) in the presence of DMAP and EDCI, followed by
ﬂash column chromatography puriﬁcation in 85% yield. Then
compound 15c was treated with glutaric anhydride at room
temperature to give the acid 16d, which was further coupled
with oridonin (1) in the presence of EDCI and DMAP in dry
dichloromethane to deliver probe 17d in 80% yield. Using
similar methodology, reaction of oridonin with intermediates
16a−c and 16e gave other ﬂuorescent probes 17a (in 91%
yield), 17b (84%), 17c (88%), and 17e (72%), respectively.
Interestingly, ﬂuorescent side chains at C-14 position of
oridonin can be highly regioselectively synthesized from
oridonin without any protection, which was consistent with
previous reports.38 In addition, the structure of compound 17d
was unambiguously identiﬁed by 2D NMR experiments,
whereby HMBC correlations were observed between the
C14−H methine resonance (δH 5.88, 1H, s) of oridonin to
13C resonances at δC 171.3 of the linker (please see Supporting
Information).
7-(Dimethylamino)coumarin-4-acetic acid (21) was obtained
in 29% overall yield by hydrolysis of the corresponding
coumarin ester (20), which was formed by the reaction
between 3-dimethylaminophenol (18) and diethyl-1,3-acetone-
dicarboxylate (19) in the presence of zinc chloride (Scheme 2).
Fluorescent probe 24c was prepared in 89% yield via ester
condensation reaction between oridonin and compound 21
directly in the presence of EDCI and DMAP in dry
dichloromethane. The other targeted ﬂuorescent probes
(24a−b) could be synthesized from intermediates 23a−b,
which were prepared using the same methods described above.
It has been widely accepted that the α,β-unsaturated ketone
system in the D-ring of ent-kaurane diterpenoids is a key
pharmacophore for their antiproliferactive activity, and
destruction of this ketone system could counteract their
anticancer eﬀects. Thus, reductive oridonin (26) and its
corresponding ﬂuorescent probe (27) were prepared as
negative controls as shown in Scheme 3. Reduction of the
double bond between C-16 and C-17 of oridonin was
accomplished by catalytic hydrogenation on 10% Pd/C in
methanol at room temperature, then ﬂash chromatography of
Scheme 3. Synthesis of Oridonin Analogues 25, 26, and Fluorescent Oridonin Probe 27a
aReagents and conditions: (a) n-caprylic acid, EDCI, DMAP, CH2Cl2, rt, 2 h; (b) 10% Pd/C, MeOH, rt, 1 h; (c) EDCI, DMAP, CH2Cl2, rt, 0.5 h.
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the evaporated residue, eluting with dichloromethane/meth-
anol (40:1) aﬀorded compound 26 in 94% yield. The
preparation of its ﬂuorescent probe 27 was carried out by
coupling compound 16d to the C-14 position of 26 in 82%
yield. On the other hand, compound 25 was employed as a
positive control, which was synthesized in 80% yield through
selective esteriﬁcation of oridonin at 14-hydroxyl group with n-
caprylic acid (Scheme 3).
Cytotoxicity. We investigated the antiproliferative activities
of nine novel ﬂuorescent oridonin probes including 17a−e,
24a−c, 27, and two oridonin analogues 25 and 26 against
human hepatocellular carcinoma Bel-7402 cells by using MTT
assay. Oridonin (1) was also tested for comparison, and the
data was summarized in Table 1. Oridonin and its 14-OH
modiﬁed derivative 25 showed good cytotoxicity against Bel-
7402 cells; however, analogue 26, whose α,β-unsaturated
ketone moiety was destructed, displayed poor antiproliferative
activity. Almost all the ﬂuorescent probes exhibited slightly
lower antiproliferative activity compared with the parent
oridonin, except probe 17d. The probes containing 3-
substituted coumarin (17a−e) maintained their cytostatic
activity better than probes containing 4-substituted coumarin
(24a−c). We also found that the length of spacer joining the
coumarin skeleton and oridonin had an eﬀect on the
antiproliferative activities of the probes. Compound 17d, with
11-atom spacer, expressed better inhibitory eﬀect on growth
than its analogues 17a−c and 17e. Although compound 24c is
more potent than 24a, giving its short spacer which may
interfere with the binding of natural product to its target and
aﬀect its mode of action, compound 24a was more suitable for
further studies.
On the basis of the above preliminary results, compounds 1,
17d, 24a, 26, and 27 were selected to further test their in vitro
antiproliferative activities on three human cancer cell lines. As
shown in Table 2, ﬂuorescent probes 17d and 24a had
cytotoxicity comparable to, or even stronger than that of
oridonin (1). However, compound 26 showed lower activity
compared to that of oridonin, especially in A549 cell line (IC50:
67.0 μM vs 10.4 μM), and its corresponding probe 27 also had
no obvious activity as expected. These results suggested that
α,β-unsaturated ketone moiety is crucial to the inhibitory
activity of oridonin and its derivatives, and the coumarin moiety
possesses low cytotoxicity.
Fluorescent Properties. As shown in Table 1, the
ﬂuorescent properties of target compounds including the
excitation and emission of probes were evaluated in dichloro-
methane at a concentration of 1 × 10−6 M by using
spectroﬂuorophotometer. All the probes exhibited signiﬁcant
diﬀerences between maximum excitation (λexc) and emission
(λem) wavelength, namely Stokes shift. The probes bearing 3-
substituted coumarin (17a−e, 27) displayed ﬂuorescence
excitation peaks at about 425 nm and the emission wavelengths
varied in the range of 454−459 nm, expressing a shift toward
the UV region compared with probe 15a. It was encouraging to
see larger Stokes shift in these probes than 15a, making them
more appropriate for the imaging studies. We speculated that
this might be attributed to the appended oridonin moiety. The
probes bearing 4-substituted coumarin (24a−c) had larger
Stokes shift (∼80 nm) with λexc at ∼380 nm and λem at ∼460
nm. Preliminary studies on the ﬂuorescent property showed
that all these probes were suitable for imaging studies.
Uptake Proﬁles of Probes. The MTT assay showed that
ﬂuorescent probes 17d and 24a had signiﬁcant antiproliferative
activities comparable to that of oridonin. However, no obvious
antiproliferative activities were observed on probes 15a and 27.
Uptake proﬁles of these probes were detected to uncover the
relationships between antiproliferative activities and uptake
using ﬂuorescence microscopy. As shown in Figure 3A, bright
ﬂuorescence staining inside the cells was observed when probes
17d and 24a were incubated at a concentration of 5 μM for 1 h
in HepG2 cells. Then, cells stained with naked coumarin dye
(15a) were used as a control to exclude the possibility that the
uptake of the ﬂuorescent oridonin probes was driven by
coumarin dye itself. As shown in Figure 3Ac, no ﬂuorescence
could be detected from cells treated with 50 μM 15a; as a
matter of fact, even at a concentration of 100 μM, no obvious
ﬂuorescence could be observed after 1 h staining (Supporting
Information, Figure S1). Unexpectedly, even at a concentration
up to 20 μM, no ﬂuorescence staining from probe 27 could be
detected after 1 h incubation (Figure 3A-d). The lack of
ﬂuorescence from controls 15a and 27 in live cells suggest that
the uptake and localization was indeed due to the natural
Table 1. Growth Inhibitory Eﬀects and Fluorescence
Properties of Target and Reference Compounds















1 94.6 94.8 37.9
15a 9.5 3.7 0.7 443 465 22
17a 94.4 72.4 11.5 422 455 32
17b 94.6 85.0 4.9 425 458 33
17c 94.6 89.9 2.7 423 457 34
17d 93.8 94.0 88.6 420 454 34
17e 94.6 70.1 1.4 424 459 35
24a 93.3 46.4 1.1 381 468 87
24b 89.2 18.7 9.3 370 459 89
24c 92.4 94.5 13.6 377 457 80
25 94.7 92.7 57.5
26 57.2 4.2 2.1
27 37.2 3.7 1.8 432 461 29
aGrowth inhibitory eﬀects of compounds 1, 17a−e, 24a−c, and 25−
27 on human hepatocellular carcinoma Bel-7402 cells. MTT assays:
Bel-7402 cells were treated with varying concentrations of indicated
compounds for 72 h. Values are the mean of three independent
experiments. bFluorescence properties were evaluated in CH2Cl2 with
compounds at a concentration of 1 × 10−6 M, λexc: maximum
excitation, λem: maximum emission.
Table 2. IC50 Values of Oridonin (1), Its Synthetic Analogue
(26), and Fluorescent Derivatives (17d, 24a, and 27) on
Inhibiting Proliferation of Human Cancer Cells (μM)a
compd HepG2 A549 Helab
1 15.2 ± 1.0 10.4 ± 0.4 17.8 ± 0.9
17d 2.6 ± 0.1 5.1 ± 0.1 2.0 ± 0.1
24a 8.8 ± 0.6 11.2 ± 0.9 4.6 ± 0.2
26 70.6 ± 4.3 67.0 ± 7.1 52.7 ± 3.9
27 144.1 ± 9.5 78.0 ± 5.2 79.6 ± 6.3
aMTT assays: cells were incubated with indicated compounds for 72
h, (means ± SD, n = 3). bHepG2 (liver hepatocellular carcinoma cell),
A549 (Human lung adenocarcinoma cell), Hela (human cervical
cancer cell).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b00408
J. Med. Chem. 2016, 59, 5022−5034
5026
product’s activity, and α,β-unsaturated ketone moiety is crucial
to the uptake of oridonin.
In parallel, we performed time- and concentration-based
uptake studies of probe 17d in HepG2 cells. The minimum
concentration of probe 17d was optimized to 1 μM (data not
shown), and the uptake of probe 17d at this concentration was
observed quickly as shown in Figure 3B. Notably, distinguish-
able ﬂuorescence could be detected in HepG2 cells in as early
as 5 min after incubation with probe 17d, and the same
phenomenon occurred when the A549 cells were incubated
with 17d (Supporting Information, Figure S2).
Intracellular Distribution of Probes 17d and 24a in
Cancer Cells. To examine whether the types of linked
coumarins would aﬀect the uptake or localization of oridonin
probes, we simultaneously investigated the diﬀerence between
probes 17d and 24a, which were linked with diﬀerent coumarin
dyes. Both A549 and HepG2 cells were treated with 1 μM 17d
or 24a for 12 h, washed with media, and imaged by a confocal
laser scanning microscope. In HepG2 cells, probe 17d appeared
more eﬀective than 24a and stronger ﬂuorescence signal could
be detected from 17d (Supporting Information, Figure S3), but
no obvious diﬀerence could be observed in A549 cells (Figure
4) and the ﬂuorescence signals of both 17d and 24a could be
detected within the cytoplasm of cells presented as spots
adjacent to the nuclear. Thus, the next subcellular localization
studies were reasonably carried out in A549 cells.
Subcellular Localization Studies. To further detail the
subcellular localization of ﬂuorescent oridonin probe 17d in
A549 cells, we costained 17d-treated cells with a panel of
organelle-speciﬁc dyes. Fortunately, confocal microscopy of
cells costained with MitoTracker Red (mitochondria speciﬁc
dye) conﬁrmed the localization of 17d in mitochondria. In
Figure 3. Uptake of probes in HepG2 cells. (A) Uptake of indicated probes in HepG2 cells: (a) 5 μM 17d for 1 h, (b) 5 μM 24a for 1 h, (c) 50 μM
15a for 1 h, (d) 20 μM 27 for 1 h. (B) Time-course uptake of 1 μM probe 17d in HepG2 cells, images were collected using ﬂuorescence microscopy:
(a) HepG2 cells were treated with 17d for 0 min, (b) 5 min, (c) 10 min, (d) 15 min, (e) 30 min, (f) 1 h. Bars denote 50 μm.
Figure 4. Live-cell imaging of probes. A549 cells were treated with 1 μM probe 17d (a) or 24a (b) for 12 h. Images were collected with excitation of
probes at λex = 405 nm and emission at λem = 460 nm, cells were imaged at 40× with an inverted confocal microscope (LSM710 NLO, Zeiss). DIC:
diﬀerential interference contrast ﬁeld. Bars denote 10 μm.
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particular, the overlap of red ﬂuorescence from the red
mitochondrial stain and the green ﬂuorescence from probe
17d provided compelling evidence in support of this conclusion
(Figure 5a). Notably, in this localization study, probe 17d was
absorbed quickly after 1 h incubation and localized to
mitochondria with a Pearson’s coeﬃcient value (Rr) of 0.979.
However, the Rr value decreased to 0.843 when cells were
treated with 17d for 3 h, and only partial overlap of these two
ﬂuorescent probes could be observed at 12 h. After 24 h, no co-
localization could be observed and the ﬂuorescence became
dispersed, which may be attributed to the cytotoxicity of probe.
Mitochondrial Membrane Potential Assay. The mito-
chondrion is an essential organelle that plays a crucial role in
energy production; its dysfunction would induce irreversible
cell apoptosis in a short time.39 Inspired by the observations in
which the ﬂuorescent oridonin probe provided direct visual
evidence for co-localization with mitochondria in A549 cells, we
speculated that these ﬂuorescent oridonin probes may reduce
mitochondrial membrane integrity and thereby aﬀect cell
proliferation.40 Thus, commercially available ﬂuorescent probe
JC-1 was used to measure the mitochondrial membrane
potential (MMP). In healthy cells, JC-1 aggregates in the
mitochondria and spontaneously forms complexes that
ﬂuoresce red. In apoptosis or necrotic cells, JC-1 exists in the
monomeric form and stains the cytosol green. As shown in
Figure 6a, treatment of A549 cells with 1 μM 17d induced the
dissipation of MMP in a time-dependent manner, as indicated
by a decrease in red ﬂuorescence emission and an increase in
green ﬂuorescence emission. The ratio of ﬂuorescent intensity
of red to green was determined and used as an indicator of cell
healthy status. The ratio began to decrease after 12 h treatment
of 1 μM 17d, and after 48 h treatment, the ratio decrease
dramatically from 1.496 to 0.312. However, no signiﬁcant
changes of MMP could be observed after the treatment of 20
μM 27 (Figure 6b).
Figure 5. Time-course of co-localization of probe 17d with MitoTracker (mitochondria speciﬁc dye) in A549 cells. Images were collected using
confocal microscopy (LSM710 NLO, Zeiss, 60×). (a) A549 cells incubated with 1 μM 17d for 1 h: right panel, cellular localization of 17d; middle
panel, overlay of two images; left panel, cellular localization of MitoTracker. A549 cells incubated with 1 μM 17d for 3 h (b), for 12 h (c), for 24 h
(d). Images were collected with excitation of probe 17d at λex = 405 nm and emission at λem = 460 nm, MitoTracker at λex = 579 nm and emission at
λem = 600 nm. Bars denote 10 μm.
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Previous investigations indicated that oridonin could induce
apoptosis through several apoptotic pathways, especially
mitochondria-dependent apoptosis.41 Therefore, we detected
the inﬂuence of oridonin on MMP using JC-1 probe. Brieﬂy,
A549 cells were ﬁrst incubated with or without 10 μM oridonin
for 36 h, then dyed with ﬂuorescent JC-1. As shown in Figure
6c, oridonin treatment in A549 cells induced the dissipation of
MMP, as indicated by a change of ﬂuorescence intensity from
red to green in treated cells. Collectively, these results
suggested that mitochondrial pathway directly participated in
apoptosis induced by oridonin.
Immunoﬂuorescence Co-localization Analysis of Cy-
tochrome c. Cytochrome c is widely believed to be localized
uniquely in the mitochondrial intermembrane space under
normal physiological conditions. The release of cytochrome c
from mitochondria to the cytosol after the dissipation of MMP,
where it activates the caspase family of proteases, is believed to
be a primary trigger leading to the onset of apoptosis.42 Thus,
we detected the localization of cytochrome c in A549 cells after
the treatment of oridonin with immunoﬂuorescence co-
localization analysis. As shown in Figure 7, in control groups,
the green-stained cytochrome c by a ﬂuorescently labeled
secondary antibody were located in the mitochondria which
were stained red by Mitotracker Red, resulting in a bright-
orange ﬂuorescence. However, when A549 cells were treated
with 3 or 5 μM oridonin for 24 or 48 h, part of the orange
ﬂuorescence was quenched and green color appeared outside,
indicating leakage of cytochrome c from mitochondria into the
cytosol. We also found that the intensity of green light was
proportional to both incubating time and concentration of
oridonin. The combination of these observations suggested the
release of cytochrome c from mitochondria to cytosol in
response to treatment with oridonin, which might be the critical
step in the process of oridonin-mediated apoptosis.
Structure−Activity Relationships Studies. Above experi-
ments clariﬁed that the loss of cancer cell viability was
associated with the decreased mitochondrial membrane
potential and the release of cytochrom c. Further studies
were conducted to explore which unique pharmacophore of
oridonin can initiate these biological responses. We compared
the localization of probe 17d when preincubated with oridonin
(1), its 14-OH modiﬁed derivative (25), and α,β-unsaturated
ketone reduction product (26), respectively. When A549 cells
were pretreated with oridonin or its analogues, both 1 and 25
could block the uptake of probe 17d eﬀectively as shown in
Figure 8a,b. However, no signiﬁcant changes in both
ﬂuorescence intensity and localization of 17d were noted
when A549 cells were pretreated with 20 μM 26 for 24 h. This
observation suggests that oridonin and its ﬂuorescent probes
act similarly in A549 cell and probe 17d might share a common
target with oridonin or its derivative 25. More importantly, the
active α,β-unsaturated ketone could bind tightly to the target in
an irreversible manner.43,44 Indeed, α,β-unsaturated ketone
moiety is a common and structurally important functionality
that is widespread in various naturally occurring products,
especially in ent-kaurane diterpenoids.45,46 As shown in Figure
Figure 6. Compounds 17d and 1 induced loss of mitochondrial membrane potential (MMP) in A549 cells analyzed by JC-1 ﬂuorescence. (a)
Independent experiments with 10000 cells per treatment condition reveal a decrease of photometric ratio of red to green ﬂuorescence after 17d
treatment, and no signiﬁcant change could be observed after 27 treatment (b). Data was represented as mean ± SD of three independent
experiments, *P < 0.05, **P < 0.01, ***P < 0.001. (c) Oridonin induced mitochondrial depolarization in A549 cells. After treatment with 10 μM 1
for 36 h, the ﬂuorescence intensity changed signiﬁcantly from red to green in treated cells. The upper panels represent the normal group, and lower
panels depict the loss of MMP after the treatment of oridonin.
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1, almost all the ent-kaurane diterpenoids that exhibit
substantial antitumor activity share this common moiety, and
this result provides direct evidence that the ent-kaurane
diterpenoids might share a common mode of action.
■ CONCLUSION
In this experiment, nine novel ﬂuorescent analogues were
designed and synthesized to visualize the anticancer mechanism
of action of oridonin. Most of the target probes displayed
satisfactory antiproliferative activities and optimal ﬂuorescent
properties. Further ﬂuorescent and biological proﬁles were
examined by using typical probes (17d, 24a, and 27) to
investigate the mode of action of oridonin in cancer cell lines. It
was demonstrated that oridonin ﬂuorescent probe 17d could be
absorbed quickly by cancer cells, and α,β-unsaturated ketone
moiety was the key pharmacophore for the anticancer activity
and uptake of oridonin. Moreover, time-based subcellular
localization studies of probe 17d in A549 cells were performed,
and the co-localization analysis illustrated the mitochondria-
speciﬁc localization of ﬂuorescent oridonin probe 17d, which
could be developed as a speciﬁc mitochondria biomarker. The
subsequent studies on mitochondrial physiology indicated that
the mitochondrial pathway is involved in oridonin-mediated
apoptosis and that cytochrome c plays an important role in the
apoptotic process.
In summary, we report an eﬀective strategy for ﬂuorescent
labeling of oridonin, which may be used for studies on other
ent-kaurane diterpenoids for which the anticancer action and
targets are currently unknown. Further progress on identi-
ﬁcation of cellular targets of oridonin and other ent-kaurane
diterpenoids will be reported in due course.
■ EXPERIMENTAL SECTION
Chemistry. General Information. Commercially available reagents
and solvents were used without further puriﬁcation. Column
chromatography was carried out on Merck silica gel 60 (200−400
mesh). 1H, 13C, and 2D NMR spectra were recorded with 300 MHz
spectrometers in the indicated solvents (TMS as internal standard).
Chemical shifts were reported in parts per million (ppm, δ) downﬁeld
from tetramethylsilane. Proton coupling patterns are described as
singlet (s), doublet (d), triplet (t), quartet (q), double doublet (dd),
multipet (m), and broad (br). Low- and high-resolution mass spectra
(LRMS and HRMS) were measured on Agilent QTOF 6520. Melting
points were taken on XT-4 micro melting point apparatus and
uncorrected. The purity of all tested compounds was characterized by
HPLC analysis, and individual compounds with a purity of ≥95% were
used for subsequent experiments (see the Supporting Information).
HPLC was performed using Phenomenex Gemini C18 (4.6 mm× 150
mm, 5 μm), and samples were detected using a wavelength of 240 nm.
Figure 7. Immunoﬂuorescence co-localization analysis reveals the release of cytochrome c from mitochondrion to cytosol during the apoptostic
process. Cells were incubated with primary antibody against cytochrome c followed by treatment with Alexa Fluor 488-conjugated (green) goat
antirabbit secondary antibody. The mitochondria were stained with Mitotracker Red (red), and cell nuclei were stained with DAPI (blue). Images
were collected using confocal microscopy (LSM710 NLO, Zeiss). (a) A549 cells incubated without oridonin, right panel; merged images, left panel;
enlarged view of representative cells. (b) A549 cells incubated with 3 μM 1 for 24 h, 48 h; (c) 5 μM 1 for 24 h (d), 48 h (e). Yellow arrow,
cytochrome c located in mitochondria; white arrow, cytochrome c released from mitochondria to cytosol. Bars denote 10 μm.
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1H NMR and 13C NMR Spectra of the Representive Compounds
and Probes. Synthesis of Probe 17d. Compound 1 (100 mg, 0.27
mmol) was dissolved in dichloromethane, then EDCI, DMAP, and
coumarin intermediates 16d (120 mg, 0.27 mmol) were added. The
reaction mixture was stirred at room temperature for 1 h. Then the
mixture was washed with 10% HCl. The organic layer was washed with
brine and dried over anhydrous Na2SO4. After ﬂash chromatography
(dichloromethane/methanol 150:1), compound 17d was obtained as a
yellow solid (171 mg, 80%); mp 130−131 °C. 1H NMR(CDCl3, 300
MHz), δ (ppm) 8.42 (1H, s), 7.37 (1H, d, J = 8.94 Hz), 6.62 (1H, dd,
J = 8.97, 2.34 Hz), 6.46 (1H, d, J = 2.16 Hz), 6.05 (1H, s), 6.07 (1H, d,
J = 10.50 Hz), 5.88 (1H, s), 5.51 (1H, s), 4.20−4.34 (3H, m, 20-CH2),
4.05−4.15 (4H, m), 3.73 (1H, m), 3.42−3.52 (5H, m), 3.17 (1H, d, J
= 9.81 Hz), 2.60 (1H, m), 2.29−2.37 (4H, m), 2.29 (1H, m), 1.97
(1H, m), 1.90 (2H, m), 1.85−1.95 (4H, m), 1.73 (1H, m), 1.68 (1H,
m), 1.58 (1H, m), 1.44 (1H, m), 1.30 (1H, m), 1.21−1.24 (2H, m),
1.24 (6H, t, J = 7.14 Hz), 1.88 (6H, s). 13C NMR(CDCl3, 75 MHz), δ
(ppm) 206.5, 172.7, 171.3, 164.2, 158.4, 158.2, 152.9, 149.9, 149.2,
131.1, 120.0, 109.5, 108.8, 107.7, 96.7, 96.1, 76.4, 74.1, 73.4, 64.5, 64.0,
63.4, 61.9, 59.7, 54.6, 45.0, 41.3, 38.7, 33.7, 33.5, 33.0, 32.5, 30.5, 30.0,
29.6, 25.4, 25.3, 21.6, 19.8, 19.8, 12.4. MS (ESI) m/z: 792.4 [M −
H]−, 794.6 [M + H]+. HR-MS (ESI) m/z: calcd for C43H56NO13 [M +
H]+ 794.3746, found 794.3765.
Synthesis of Probe 24a. Following the procedure described for the
preparation of compound 17d, compound 24a was synthesized as a
pale-yellow solid (yield 73%); mp 147−148 °C. 1H NMR (CDCl3,
300 MHz): δ (ppm) 1.09 (s, 3H), 1.11 (s, 3H), 1.26 (m, 4H), 1.61 (m,
7H), 1.97 (m, 1H), 2.22 (m, 1H), 2.57 (m, 4H), 3.07 (s, 6H,
N(CH3)2), 3.15 (m, 1H), 3.50 (m, 1H), 3.74 (s, 2H), 4.05 (d, J = 8.7
Hz, 1H), 4.28 (m, 5H), 5.52 (s, 1H), 5.90 (s, 1H), 6.04 (m, 1H), 6.09
(s, 1H), 6.15 (s, 1H, Ar-H), 6.57 (s, 1H, Ar-H), 6.66 (d, J = 9.0 Hz,
1H, Ar-H), 7.43 (d, J = 9.0 Hz, 1H, Ar-H). 13C NMR (CDCl3, 75
MHz): δ (ppm) 206.0, 171.3, 170.3, 168.5, 161.3, 155.4, 152.5, 149.4,
147.7, 124.8, 119.7, 110.2, 108.6, 107.9, 97.8, 95.6, 75.7, 73.8, 72.9,
62.8, 62.5, 61.7, 61.5, 59.0, 54.2, 40.8, 39.6, 38.2, 37.3, 33.2, 32.1, 30.0,
29.8, 29.4, 29.1, 21.2, 19.3. MS (ESI) m/z: 736.3 [M − H]−, 738.5 [M
+ H]+. HR-MS (ESI) m/z: calcd for C39H48NO13 [M + H]
+ 738.3129,
found 738.3131.
Synthesis of Compound 25. Compound 1 (200 mg, 0.55 mmol)
was dissolved in dichloromethane, then EDCI, DMAP and n-caprylic
acid (79 mg, 0.55 mmol) were added. The reaction mixture was stirred
at room temperature for 2 h. Then the mixture was washed with 10%
HCl. The organic layer was washed with brine and dried over
anhydrous Na2SO4. After ﬂash chromatography (dichloromethane/
methanol 200:1), compound 25 was obtained as a white solid (216
mg, 80%); mp 69−71 °C. 1H NMR (CDCl3, 300 MHz): δ (ppm) 6.24
(d, J = 9.4 Hz, 1H), 6.13 (s, 1H), 5.81 (s, 1H), 5.48 (s, 1H), 4.37 (s,
1H), 3.30, 4.07 (dd, JA = JB = 9.6 Hz, each 1H), 3.75 (m, 1H), 3.50 (m,
1H), 3.18 (d, J = 9.6 Hz, 1H), 2.62 (m, 1H), 2.27 (m, 3H), 2.01 (m,
1H), 1.54 (m, 8H), 1.24 (m, 10H), 1.10 (s, 6H), 0.82 (m, 3H). 13C
NMR (CDCl3, 75 MHz): δ (ppm) 206.7, 172.1, 149.8, 120.0, 96.2,
76.7, 73.8, 73.1, 63.5, 61.8, 59.9, 54.6, 41.3, 41.2, 38.6, 34.5, 33.7, 32.5,
31.5, 30.5, 30.3, 29.8, 29.6, 24.8, 24.6, 22.5, 21.6, 13.8. MS (ESI) m/z:
491.3 [M + H]+. HR-MS (ESI) m/z: calcd for C28H42NaO7 [M +
Na]+ 513.2823, found 513.2841.
Synthesis of Compound 26. Compound 1 (200 mg) was dissolved
in methyl alcohol (10 mL), then 10% Pd/C 20 mg was added to this
solution. The mixture was stirred under hydrogen atmosphere at room
temperature for 1 h. The reaction mixture was ﬁltered, and the solvent
was evaporated under reduced pressure. Flash chromatography of the
residue, eluting with dichloromethane−methanol (40:1), gave
compound 26 (188 mg, 94%) as a white solid; mp 206−207 °C. 1H
NMR (DMSO-d6, 300 MHz): δ (ppm) 0.96 (s, 3H), 0.99 (s, 3H),
1.03(d, J = 7.2 Hz, 3H), 1.06 (m, 1H), 1.19 (m, 2H), 1.29 (m, 1H),
1.47 (m, 4H), 1.62 (m, 1H), 1.88 (m, 1H), 2.00 (m, 1H), 2.32 (m,
1H), 2.91 (m, 1H), 3.43 (m, 1H), 4.06, 3.81 (dd, JA = JB = 10.8 Hz,
each 1H, 20-CH2), 4.06 (d, J = 4.8 Hz, 1H), 4.79 (s, 1H), 5.73 (d, J =
11.1 Hz, 1H), 6.09 (s, 1H), 6.73 (s, 1H). 13C NMR (DMSO-d6, 75
MHz): δ (ppm) 224.6, 96.7, 96.5, 73.2, 73.0, 71.4, 62.7, 61.1, 60.2,
52.6, 44.7, 38.3, 38.2, 33.3, 32.4, 29.2, 21.4, 19.0, 18.2, 10.1. MS(ESI)
m/z: 367.8 [M + H]+. HR-MS (ESI) m/z: calcd for C20H30NaO6 [M +
Na]+ 389.1935, found 389.1939. The β-orientation of 17-CH3 has
been conﬁrmed by literature report.47
Synthesis of Probe 27. Following the procedure described for the
preparation of compound 17d, compound 27 was synthesized as a
yellow solid; (yield 82%); mp 126−127 °C. 1H NMR (CDCl3, 300
MHz): δ (ppm) 1.01 (s, 3H), 1.06 (m, 3H), 1.14 (s, 3H), 1.16 (t, J =
7.2 Hz, 6H, N(CH2CH3)2), 1.52 (m, 7H), 1.85 (m, 5H), 1.90 (m,
4H), 2.21 (m, 1H), 2.34 (m, 4H), 2.58 (m, 1H), 2.78 (m, 1H), 3.41
(q, J = 7.2 Hz, 4H, N(CH2CH3)2), 3.60 (m, 1H), 4.19, 3.96 (dd, JA =
JB = 10.8 Hz, each 1H, 20-CH2), 4.08 (m, 2H), 4.27 (m, 2H), 5.72 (d,
J = 11.4 Hz, 1H), 5.90 (d, J = 1.2 Hz, 1H), 6.39 (d, J = 2.4 Hz, 1H,
Figure 8. Confocal ﬂuorescent images detailing the impact of compounds 1, 25, and 26 on the subcellular localization of probe 17d. A549 cells were
incubated with 20 μM oridonin (1) (a), 1 μM 25 (b), 20 μM 26 (c) for 24 h, then 1 μM probe 17d for 1 h. Images were collected with excitation of
probe at λex = 405 nm and emission at λem = 460 nm, cells were imaged at 40× with an inverted confocal microscope (LSM710 NLO, Zeiss). DIC:
diﬀerential interference contrast ﬁeld. Bars denote 10 μm.
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Ar−H), 6.54 (dd, J = 9.0, 2.4 Hz, 1H, Ar-H), 7.30 (d, J = 9.0 Hz, 1H,
Ar-H), 8.35 (1H, s, Ar-H). 13C NMR (CDCl3, 75 MHz): δ (ppm)
221.9, 172.1, 170.7, 158.0, 152.5, 130.6, 125.0, 109.1, 107.2, 96.2, 95.4,
76.5, 73.8, 72.9, 64.1, 63.6, 63.0, 61.0, 60.2, 59.5, 54.0, 53.0, 45.6, 44.6,
40.5, 38.2, 38.0, 36.6, 33.2, 33.1, 32.6, 32.0, 31.7, 29.8, 29.2, 24.9, 24.8,
20.8, 19.3, 13.4, 11.9, 9.3. MS (ESI) m/z: 794.4 [M − H]−, 796.6 [M
+ H]+. HR-MS (ESI) m/z: calcd for C43H58NO13 [M + H]
+ 796.3903,
found 796.3907.
Cytotoxicity Assay. The eﬀect of oridonin and its derivatives on the
cytotoxicity of cancer cells was determined by MTT assay. Brieﬂy, the
MTT assay was performed in 96-well plates using HepG2, A549, and
HeLa cells. These cells (5 × 104 cells/mL) at the log phase of their
growth cycle were added to each well (100 μL/well), then treated in
the presence or absence of test compounds and incubated for 72 h at
37 °C in a humidiﬁed atmosphere of 5% CO2. After terminating the
treatment, 20 μL of MTT solution (5 mg/mL) was added to each
cultured medium and cells were incubated for another 4 h. Then,
DMSO was added to each well (150 μL/well). After 10 min at room
temperature, the OD value of each well was measured on a microplate
reader (BIO-RAD Instruments Inc. no. 550) at the wavelength of 490
nm. In these experiments, the negative reference agent was 0.1%
DMSO, and paclitaxel at the concentration of 10 mg/mL was used as
the positive reference.
Fluorescent Cell Staining. For ﬂuorescence observation, A549 cells
were seeded in Lab-Tek four-chambered slides (Nalge Nunc
International, Naperville, IL, USA) and incubated with various
concentrations of ﬂuorescent oridonin derivatives for diﬀerent time.
After incubation, cells were washed with PBS for three times and
antifade mounting medium was added. Images were obtained with an
inverted confocal microscope (LSM710 NLO, Zeiss). Each experiment
was repeated three times, and selected images were presented in the
manuscript.
Subcellular Localization Studies. A549 cells were seeded in Lab-
Tek four-chambered slides (Nalge Nunc International, Naperville, IL,
USA), pretreated with 1 μM 17d for 1, 3, 12, 24 h, washed with PBS,
and incubated with MitoTracker (Life Technologies Inc., USA,
MitoTracker Red CMXRos, 200 nM) for another 0.5 h. After being
washed with cold PBS, the cells were ﬁxed with paraformaldehyde and
washed before they were imaged with confocal laser scanning
microscopy (LSM710 NLO, Zeiss).
JC-1 Assay to Determine MMP. The MMP was determined with
the dual-emission mitochondrial dye JC-1. Cells were loaded with 10
μg/mL JC-1 dye for 30 min at 37 °C and then washed for 5 min in
PBS buﬀer. After incubation, samples were immediately assessed for
red and green ﬂuorescence by a microplate reader. The ﬂuorescent
signal of monomers is measured with an excitation wavelength of 490
nm and an emission wavelength of 535 nm. The ﬂuorescent signal of
aggregates is detected with an excitation wavelength of 525 nm and an
emission wavelength of 600 nm. Besides, the ﬂuorescent signal can
also be detected using confocal microscope. All the experiments were
performed in triplicate.
Immunoﬂuorescence Co-localization Analysis. A549 cells were
grown on coverslips inside a Petri dish ﬁlled with the appropriate
culture medium. When cells have reached the desired conﬂuency, the
media was removed from the dish and prewarmed (37 °C) staining
solution containing MitoTracker probe was added. The cells were
incubated for 30 min under growth conditions. After staining was
complete, staining solution was replaced with washing buﬀer. After
ﬁxing with 4% formaldehyde and permeabilizing with 0.2% TritonX-
100, cells were blocked with 5% BSA (Amresco) for 1 h at room
temperature. Cells were incubated with primary antibody against
cytochrome c (Biolegend) overnight at 4 °C, followed by incubated
with Alexa Fluor 488-conjugated goat antirabbit secondary antibody
(Molecular Probe, Grand Island, NY) for 2 h in room temperature.
Nuclei were counter stained with DAPI. Cells were imaged with
confocal laser scanning microscopy (LSM710 NLO, Zeiss).
Fluorescence excitation and emission spectra for MitoTracker Red
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(23) Böttcher, T.; Pitscheider, M.; Sieber, S. A. Natural products and
their biological targets: proteomic and metabolomic labeling strategies.
Angew. Chem., Int. Ed. 2010, 49, 2680−2698.
(24) Ziegler, S.; Pries, V.; Hedberg, C.; Waldmann, H. Target
identification for small bioactive molecules: finding the needle in the
haystack. Angew. Chem., Int. Ed. 2013, 52, 2744−2792.
(25) Terai, T.; Nagano, T. Small-molecule fluorophores and
fluorescent probes for bioimaging. Pfluegers Arch. 2013, 465, 347−359.
(26) Yun, S. W.; Kang, N. Y.; Park, S. J.; Ha, H. H.; Kim, Y. K.; Lee, J.
S.; Chang, Y. T. Diversity oriented fluorescence library approach
(DOFLA) for live cell imaging probe development. Acc. Chem. Res.
2014, 47, 1277−1286.
(27) DeGuire, S. M.; Earl, D. C.; Du, Y.; Crews, B. A.; Jacobs, A. T.;
Ustione, A.; Daniel, C.; Chong, K. M.; Marnett, L. J.; Piston, D. W.;
Bachmann, B. O.; Sulikowski, G. A. Fluorescent probes of the
apoptolidins and their utility in cellular localization studies. Angew.
Chem., Int. Ed. 2015, 54, 961−964.
(28) Li, C.; Dong, T.; Li, Q.; Lei, X. G. Probing the anticancer
mechanism of (−)-ainsliatrimer A through diverted total synthesis and
bioorthogonal ligation. Angew. Chem., Int. Ed. 2014, 53, 12111−12115.
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